Oncolytic Viruses in Glioblastoma

Summary

This project investigates the use of oncolytic virotherapy as a novel treatment for glioblastoma (GBM), a highly aggressive brain cancer with limited treatment options and poor survival rates. GBM is characterized by its genetic and epigenetic heterogeneity, which contributes to resistance against conventional therapies like chemotherapy and radiation. The study focuses on Delytact (Teserpaturev/G47), an oncolytic virus derived from the herpes simplex virus, which selectively infects and destroys cancer cells while sparing healthy ones. Clinical trials in Japan have shown promising results, with Delytact significantly improving survival rates and enhancing the tumor's responsiveness to immune attacks. This therapy works by directly lysing tumor cells and converting the tumor microenvironment from immunosuppressive to immunostimulatory, making it more susceptible to other treatments. Although oncolytic virotherapy is still in its experimental stages, its ability to target the unique properties of glioblastomas suggests it could become an integral part of future treatment regimens, especially when combined with existing therapies like chemotherapy and radiotherapy.

Video Presentation

Impact Statement

Hey! I'm Gautham, a student from India. I had a fantastic experience working on a project where I examined the application of oncolytic viruses (genetically remodified viruses that target cancer cells) in violent brain tumours like glioblastomas. Aggressive cancers like these require novel therapeutics, which prompted me to further research in this field. This summer program explored several specialized and foundational aspects of molecular biology, bridging the knowledge gap between school and the scientific world. These valuable insights can give you a larger picture of what is happening in the fields of medicine, biotechnology and many other areas. Moreover, despite facing challenges with time zones in India, the mentors were exceptionally supportive and accommodating.

Report White Paper

(Click to view the full report)

_By: Gautham Anand_

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of Elio Academy.

More Projects